First Tracks Biotherapeutics

First Tracks Biotherapeutics https://validator.w3.org/feed/docs/rss2.html John Schmid Home Our Science Rosnilimab Contact us Eosinophilic Esophagitis Patients & Families ANB101 Our Pipeline Celiac Disease First Tracks Biotherapeutics Debuts on Nasdaq to Advance Therapies for Autoimmune Diseases Overview Luisa Salter-Cid, Ph.D. John Orwin Discovery of a Novel High Affinity Anti-Human CD122 Antagonist Monoclonal Antibody (ANB033) that Abrogates IL-2 and IL-15 Signaling for the Treatment of T Cell-Mediated Inflammatory and Autoimmune Diseases Rosnilimab, a Selective and Potent Depleter of Pathogenic T Cells, Demonstrates Efficacy, Safety and Translational Proof of Mechanism in a Rheumatoid Arthritis Phase 2B Trial Cailin Sibley, M.D., MHS, FACR Privacy Policy Terms of Use Careers About Us Martin Dahl, Ph.D. Priya Raina Daniel Faga Dennis Fenton, Ph.D. John G. Monroe, Ph.D. Daniel Faga Ben Stone Synovial Expression Levels of PD-1, the Target of Rosnilimab, Correlate with Disease Activity and Persist Across Disease Stages and Lines of Therapy in Rheumatoid Arthritis J. Anthony Ware, M.D. Paul F. Lizzul, M.D., Ph.D., M.P.H, M.B.A. Monique da Silva David McKeon Beth Mueller Ajim Tamboli Magda Marquet, Ph.D. Rita Jain, M.D. Dolca Thomas, M.D. Christopher Hunter, Ph.D. ANB033